Cardiol Therapeutics Inc. SEC filings CRDL
Cardiol Therapeutics Inc. has 188 filings in SEC EDGAR's recent list, going back to Mar 29, 2017. Its latest annual report, Form 40-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 40-F | Annual report (Canadian issuer) | Mar 31, 2026 | Dec 31, 2025 |
| 40-F | Annual report (Canadian issuer) | Mar 31, 2025 | Dec 31, 2024 |
| 20-F | Annual report (foreign issuer) | Apr 1, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | Mar 29, 2023 | Dec 31, 2022 |
| 40-F/A | Amended annual report (Canadian issuer) | Apr 20, 2022 | Dec 31, 2021 |
| 40-F | Annual report (Canadian issuer) | Mar 24, 2022 | Dec 31, 2021 |
Showing 6 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRDL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- Oakville, Ontario, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1702123
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.